Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Donepezil + scopolamine is a combination of two pharmaceutical agents with opposing actions on the cholinergic system. Donepezil is an acetylcholinesterase inhibitor that increases acetylcholine levels in the brain, primarily used to treat cognitive symptoms of Alzheimer's disease and other dementias by enhancing cholinergic neurotransmission[3][5][6]. Scopolamine, also known as hyoscine, is a muscarinic acetylcholine receptor antagonist that blocks the action of acetylcholine at muscarinic receptors, leading to anticholinergic effects such as sedation and memory impairment. This combination is not used therapeutically due to their antagonistic mechanisms; in fact, co-administration may reduce or negate the benefits of each drug[1]. In research settings, scopolamine is sometimes used to induce temporary cognitive deficits for testing potential cognition-enhancing drugs like donepezil[2][4][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on donepezil + scopolamine.